FDA warns Shire about overstating benefits of ADHD drug Intuniv

06/30/2010 | Bloomberg Businessweek

The FDA sent a warning letter to Shire saying that promotional materials for Intuniv, an extended-release drug for attention-deficit/hyperactivity disorder, present "unsubstantiated effectiveness claims" and "omit and minimize important risk information." A Shire spokesman said the company is "reviewing information and working closely with the FDA in order to update the materials with the correct information."

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA